Ebola Entry and the ZMapp Cocktail

Erica Ollmann Saphire, Ph.D. Immunology & Microbial Science The Scripps Research Institute

Monday, October 6, 14

Ebola virus



50-90% lethal



Monday, October 6, 14

Ebola virus has one molecule that it uses to enter cells

Ebola virus has one molecule that it uses to enter cells

"GP" for GlycoProtein

Ebola virus has one molecule that it uses to enter cells

"GP" for GlycoProtein

GP-studded membrane





Ebola virus GP



Ebola virus GP



Ebola virus GP



Sugar-rich mucin domains attached at top





What does the complete Ebola molecule look like?





Mucin domains triple its size



Mucin domains triple its size (a wolf in sheep's clothing)



Mucin domains triple its size (a wolf in sheep's clothing) also tricky in another way...





Reshapes itself as it enters the cell.



Reshapes itself as it enters the cell. This is what happens:





Cell swallows virus by macropinocytosis...

Monday, October 6, 14



Cell swallows virus by macropinocytosis... Once virus is in the endosome,





before cleavage





after cleavage



after cleavage

Monday, October 6, 14

Two forms of Ebola surface molecule.



Two forms of Ebola surface molecule.

Monday, October 6, 14





subject to immune surveillance competent for receptor binding

Two forms of Ebola surface molecule.





Many target sites are lost.



Many target sites are lost. Other sites are hidden.



Many target sites are lost. Other sites are hidden.

What works? What "neutralizes" the virus?




Human antibody, from 1995 survivor called KZ52



Antibody KZ52:





Antibody KZ52: Works in test tubes.



Antibody KZ52: Works in test tubes. Works in mice.



Antibody KZ52: Works in test tubes. Works in mice. Works in guinea pigs.



Antibody KZ52: Works in test tubes. Works in mice. Works in guinea pigs. Does not save monkeys.



Antibody KZ52: Works in test tubes. Works in mice. Works in guinea pigs. Does not save monkeys.

KZ52 was the best antibody we had against Ebola.



Antibody KZ52: Works in test tubes. Works in mice. Works in guinea pigs. Does not save monkeys.

KZ52 was the best antibody we had against Ebola.

Does this mean antibodies will not work against Ebola?

No - <u>Mixtures</u> of antibodies cure infection! even after severe disease has developed No - <u>Mixtures</u> of antibodies cure infection! even after severe disease has developed

What are these Ebola-curing antibodies?











These don't work in test tubes...



These don't work in test tubes... Yet, they save the lives of infected animals.



These don't work in test tubes... Yet, they save the lives of infected animals.





Does not protect



Does not protect





GP478-474 GP478-492











GP478-474 GP478-492









One year ago:

One year ago: we have >150 anti-Ebola antibodies...

One year ago: we have >150 anti-Ebola antibodies... Which are best? One year ago: we have >150 anti-Ebola antibodies... Which are best? How would we know? One year ago: we have >150 anti-Ebola antibodies... Which are best? How would we know? Must we have a mixture? One year ago: we have >150 anti-Ebola antibodies... Which are best? How would we know? Must we have a mixture? How many should go in? One year ago: we have >150 anti-Ebola antibodies... Which are best? How would we know? Must we have a mixture? How many should go in? Which do we combine?
One year ago: we have >150 anti-Ebola antibodies... Which are best? How would we know? Must we have a mixture? How many should go in? Which do we combine?

We need to cure this virus.

Viral Hemorrhagic Fever Immunotherapeutic Consortium

PROJECT TRACKING INTRANET

ABOUT THE VIC CONTACT

Q

Site Search



Welcome to the Viral Hemorrhagic Fever Immunotherapeutic Consortium

Objectives

Development and provision of highly effective post-exposure immunotherapeutics against the Ebola, Marburg, Sudan, Lassa, Lujo, Machupo and Junin viruses that cause hemnorrhagic fever.

Collaboration

We are an open, non-profit, 20+ investigator research consortium that spans four continents. We invite samples, input, and collaboration from researchers, NGOs and governmental bodies to help bring these emergency treatments to the clinic.

LATEST NEWS

Find as an Facebook

Lassa virus antibodies from human survivors confer 100% post-exposure protection.

International commercial partnership between Mapp Biopharmaceutical and Defyrus Inc. to advance Ebola virus immunotherapeutic to clinic.

Structure of Marburg virus GP - receptor complex provides new direction for antiviral development.

Novel antibodies against Marburg virus confer proection via a variety of mechanisms.

You lub



\$28 million TSRI-led global collaboration: Find best treatment from all available in the world



Welcome to the Viral Hemorrhagic Fever Immunotherapeutic Consortium

Objectives

Development and provision of highly effective post-exposure immunotherapeutics against the Ebola, Marburg, Sudan, Lassa, Lujo, Machupo and Junin viruses that cause hemnorrhagic fever.

Collaboration

We are an open, non-profit, 20+ investigator research consortium that spans four continents. We invite samples, input, and collaboration from researchers, NGOs and governmental bodies to help bring these emergency treatments to the clinic.

LATEST NEWS

Find us on Facebook

Lassa virus antibodies from human survivors confer 100% post-exposure protection.

International commercial partnership between Mapp Biopharmaceutical and Defyrus Inc. to advance Ebola virus immunotherapeutic to clinic.

Structure of Marburg virus GP - receptor complex provides new direction for antiviral development.

Novel antibodies against Marburg virus confer proection via a variety of mechanisms.



Ist stage of this collaboration = ZMapp "mash-up" of MB-003 and ZMAb cocktails

Mapp Bio USAMRIID Public Health Agency of Canada

Ist stage of this collaboration = ZMapp "mash-up" of MB-003 and ZMAb cocktails

Mapp Bio USAMRIID Public Health Agency of Canada

ZMapp identified ~February 2014

Ist stage of this collaboration = ZMapp "mash-up" of MB-003 and ZMAb cocktails

Mapp Bio USAMRIID Public Health Agency of Canada

ZMapp identified ~February 2014 Ebola outbreak started Dec. 2013, exploded July-August 2014

Experimental drug likely saved Ebola patients

By Dr. Sanjay Gupta and Danielle Dellorto, CNN updated 8:22 PM EDT, Tue August 5, 2014







WTHIS SOURCE: EBOLA VICTIM'S CONDITION "REVERSED" HOUR WITHIN ONE HOUR OF TAKING SECRET SERUM

August 2014

Source: CNN



British Ebola patient discharged from hospital after ZMapp treatment

LONDON Wed Sep 3, 2014 3:50pm BST

Two Liberian medical workers discharged after recovering from Ebola

By Nima Elbagir and Joshua Berlinger, CNN updated 5:16 PM EDT, Sat August 30, 2014



The 53-year-old surgeon feels even more certain that ZMapp was crucial in saving a Liberian health worker, Kyndy Kobbah, who was in a coma in critical condition when she received it. "If it wasn't for ZMapp, she wouldn't have made it," he said.

"Everybody was amazed. Nobody gave her a chance to survive. She got her recovery because of ZMapp. If they can expedite the production of it, they should try, because we really need it."



Spanish priest infected with Ebola to receive experimental treatment



Ebola Virus: Infected Priest Has Died in Spain

Priest Evacuated From Liberia Has Died in Madrid Hospital











Directly and immediately apply molecular structure to global health





My lab at The Scripps Research Institute



Dr. Carolyn Keierleber, TSRI Dr. Laurence Cagnon, TSRI NIAID Burroughs Wellcome Fund



Monday, October 6, 14